ResMed (RMD) Stock May Be 31% Undervalued After Soft FY27 Outlook

ResMed stock has lagged over the past year, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples currently point to the shares trading at a discount to what the underlying cash flows may justify. ResMed has returned 26.3% over the past 3 years, which suggests that longer term holders have still seen gains despite the recent share price weakness. Recent pressure around a softer outlook and suspended ventilator sales can weigh on sentiment, while...